• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Tuesday's Intraday Session

    10/3/23 1:31:02 PM ET
    $ALXO
    $EHAB
    $FEMY
    $GRTS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medical/Nursing Services
    Health Care
    Get the next $ALXO alert in real time by email

    Gainers

    • POINT Biopharma Global (NASDAQ:PNT) stock rose 85.4% to $12.39 during Tuesday's regular session. POINT Biopharma Global's stock is trading at a volume of 32.1 million shares as of 13:30 EST. This is 5961.6% of its average full-day volume over the last 100 days. The company's market cap stands at $1.3 billion.
    • SeaStar Medical Holding (NASDAQ:ICU) stock moved upwards by 56.09% to $0.65. SeaStar Medical Holding's stock is trading at a volume of 148.5 million shares as of 13:30 EST. This is 6003.0% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $12.6 million.
    • ALX Oncology Holdings (NASDAQ:ALXO) stock rose 50.27% to $7.23. Trading volume for this security as of 13:30 EST is 35.6 million, which is 22305.6% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $297.4 million.
    • MSP Recovery (NASDAQ:LIFW) stock rose 28.23% to $0.26. MSP Recovery's stock is trading at a volume of 113.3 million shares as of 13:30 EST. This is 325.7% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $84.9 million.
    • Leap Therapeutics (NASDAQ:LPTX) stock increased by 22.3% to $1.59. Leap Therapeutics's stock is trading at a volume of 2.4 million shares as of 13:30 EST. This is 1002.0% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $40.6 million.
    • Gritstone Bio (NASDAQ:GRTS) stock increased by 20.93% to $2.08. As of 13:30 EST, Gritstone Bio's stock is trading at a volume of 4.3 million, which is 408.8% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $193.5 million.

    Losers

    • SmileDirectClub (NASDAQ:SDC) stock decreased by 39.5% to $0.1 during Tuesday's regular session. Trading volume for SmileDirectClub's stock is 37.4 million as of 13:30 EST. This is 1212.7% of its average full-day volume over the last 100 days. The company's market cap stands at $13.0 million.
    • Femasys (NASDAQ:FEMY) stock declined by 33.45% to $2.59. As of 13:30 EST, this security is trading at a volume of 15.6 million shares, making up 141.4% of its average full-day volume over the last 100 days. The company's market cap stands at $39.0 million.
    • Enhabit (NYSE:EHAB) shares declined by 22.94% to $9.04. Trading volume for Enhabit's stock is 1.5 million as of 13:30 EST. This is 249.6% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $452.9 million.
    • Turnstone Biologics (NASDAQ:TSBX) stock declined by 16.95% to $2.77. The company's market cap stands at $63.2 million.
    • Catheter Precision (AMEX:VTAK) shares decreased by 15.67% to $0.38. The current volume of 74.3K shares is 209.7% of Catheter Precision's average full-day volume over the last 100 days (last updated at 13:30 EST). The company's market cap stands at $2.4 million.
    • PaxMedica (NASDAQ:PXMD) stock fell 15.24% to $0.28. The current volume of 340.2K shares is 43.1% of PaxMedica's average full-day volume over the last 100 days (last updated at 13:30 EST). The company's market cap stands at $4.7 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $ALXO alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ALXO
    $EHAB
    $FEMY
    $GRTS

    CompanyDatePrice TargetRatingAnalyst
    ALX Oncology Holdings Inc.
    $ALXO
    3/6/2026$6.00Buy
    UBS
    Enhabit Inc.
    $EHAB
    3/6/2026$13.80Buy → Hold
    TD Cowen
    Enhabit Inc.
    $EHAB
    1/22/2026$14.00Perform → Outperform
    Oppenheimer
    Enhabit Inc.
    $EHAB
    1/13/2026$12.00Hold → Buy
    TD Cowen
    Enhabit Inc.
    $EHAB
    1/8/2026$12.00Neutral → Buy
    UBS
    Enhabit Inc.
    $EHAB
    1/7/2026$10.50Hold
    Truist
    Femasys Inc.
    $FEMY
    11/20/2025$6.50Buy
    Laidlaw
    ALX Oncology Holdings Inc.
    $ALXO
    11/13/2025$4.00Buy
    Jefferies
    More analyst ratings

    $ALXO
    $EHAB
    $FEMY
    $GRTS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    UBS resumed coverage on ALX Oncology with a new price target

    UBS resumed coverage of ALX Oncology with a rating of Buy and set a new price target of $6.00

    3/6/26 8:38:03 AM ET
    $ALXO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Enhabit Inc. downgraded by TD Cowen with a new price target

    TD Cowen downgraded Enhabit Inc. from Buy to Hold and set a new price target of $13.80

    3/6/26 8:25:46 AM ET
    $EHAB
    Medical/Nursing Services
    Health Care

    Enhabit Inc. upgraded by Oppenheimer with a new price target

    Oppenheimer upgraded Enhabit Inc. from Perform to Outperform and set a new price target of $14.00

    1/22/26 8:46:17 AM ET
    $EHAB
    Medical/Nursing Services
    Health Care

    $ALXO
    $EHAB
    $FEMY
    $GRTS
    SEC Filings

    View All

    Enhabit Inc. filed SEC Form 8-K: Leadership Update

    8-K - Enhabit, Inc. (0001803737) (Filer)

    2/27/26 4:27:47 PM ET
    $EHAB
    Medical/Nursing Services
    Health Care

    ALX Oncology Holdings Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - ALX ONCOLOGY HOLDINGS INC (0001810182) (Filer)

    2/27/26 8:05:25 AM ET
    $ALXO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form DEFA14A filed by Enhabit Inc.

    DEFA14A - Enhabit, Inc. (0001803737) (Filer)

    2/26/26 4:06:39 PM ET
    $EHAB
    Medical/Nursing Services
    Health Care

    $ALXO
    $EHAB
    $FEMY
    $GRTS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    SeaStar Medical Announces Completion of FDA Enrollment Requirement for SAVE Surveillance Registry Evaluating QUELIMMUNE Safety for Pediatric AKI

    DENVER, March 05, 2026 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (NASDAQ:ICU), a commercial-stage healthcare company, announced today that it has completed the required enrollment in the SAVE Registry, a Post-Approval Study (PAS) required by the FDA that is designed to confirm the safety of the QUELIMMUNE™ therapy as a treatment for children with acute kidney injury (AKI) due to sepsis or a septic condition requiring renal replacement therapy (RRT). The registry has successfully enrolled 50 patients, and the company will be reporting the 28-day safety results from the SAVE Registry to the FDA upon completion of its analysis of the data. "The early results from the SAVE Regis

    3/5/26 8:20:00 AM ET
    $ICU
    Medical/Dental Instruments
    Health Care

    Enhabit Reports Fourth Quarter 2025 Financial Results

    Enhabit, Inc. (NYSE:EHAB), a leading home health and hospice care provider, today reported its results of operations for the fourth quarter ended Dec. 31, 2025. "Our fourth quarter 2025 results capped a pivotal year for Enhabit, delivering an emerging growth story with year over year increases in patient census, revenue and Adjusted EBITDA," said Barb Jacobsmeyer, CEO and president of Enhabit. "The consistent execution of our strategy throughout the year materially improved free cash flow, enabling us to further strengthen our balance sheet, positioning us well to accelerate growth and investment in 2026." QUARTERLY PERFORMANCE - CONSOLIDATED Net service revenue of $270.4 million

    3/4/26 4:10:00 PM ET
    $EHAB
    Medical/Nursing Services
    Health Care

    Femasys Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    ATLANTA, Feb. 27, 2026 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ:FEMY), a leading biomedical innovator making fertility and non-surgical permanent birth control more accessible and cost-effective to women worldwide, announced today it has granted to two new non-executive employees who began their employment with Femasys in February 2026 options to purchase 185,000 shares of Femasys common stock. These inducement grants were granted at an exercise price per share of $0.50 and $0.57, equal to the closing price of Femasys common stock on the date of employment as reported by Nasdaq. This grant was approved by the Compensation Committee of Femasys' Board of Directors and made as an inducement

    2/27/26 5:26:33 PM ET
    $FEMY
    Medical/Dental Instruments
    Health Care

    $ALXO
    $EHAB
    $FEMY
    $GRTS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Goodman Corey S bought $4,999,999 worth of shares (3,184,713 units at $1.57) (SEC Form 4)

    4 - ALX ONCOLOGY HOLDINGS INC (0001810182) (Issuer)

    2/4/26 4:15:59 PM ET
    $ALXO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Baird Jennifer A bought $987 worth of shares (4,200 units at $0.24), increasing direct ownership by 13% to 36,200 units (SEC Form 4)

    4 - SeaStar Medical Holding Corp (0001831868) (Issuer)

    12/22/25 6:55:38 PM ET
    $ICU
    Medical/Dental Instruments
    Health Care

    Chief Financial Officer Messinger Michael bought $5,098 worth of shares (14,500 units at $0.35), increasing direct ownership by 483% to 17,500 units (SEC Form 4)

    4 - SeaStar Medical Holding Corp (0001831868) (Issuer)

    12/11/25 6:49:59 PM ET
    $ICU
    Medical/Dental Instruments
    Health Care

    $ALXO
    $EHAB
    $FEMY
    $GRTS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Chief Medical Officer Klencke Barbara

    4 - ALX ONCOLOGY HOLDINGS INC (0001810182) (Issuer)

    3/5/26 4:05:06 PM ET
    $ALXO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    New insider Klencke Barbara claimed ownership of 120,000 shares (SEC Form 3)

    3 - ALX ONCOLOGY HOLDINGS INC (0001810182) (Issuer)

    3/5/26 4:01:03 PM ET
    $ALXO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    General Counsel and Secretary Black Dylan C covered exercise/tax liability with 11,054 shares and was granted 19,228 shares, increasing direct ownership by 11% to 84,499 units (SEC Form 4)

    4 - Enhabit, Inc. (0001803737) (Issuer)

    3/3/26 5:49:14 PM ET
    $EHAB
    Medical/Nursing Services
    Health Care

    $ALXO
    $EHAB
    $FEMY
    $GRTS
    Leadership Updates

    Live Leadership Updates

    View All

    SeaStar Medical Announces Appointment of Michael Messinger as CFO

    DENVER, Nov. 17, 2025 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (NASDAQ:ICU), a commercial-stage healthcare company focused on transforming treatments for critically ill patients facing organ failure and potential loss of life, announced today that Michael Messinger, a seasoned healthcare executive with over 25 years of industry experience, has joined SeaStar Medical as Chief Financial Officer. "Mike brings to SeaStar Medical a breadth of financial expertise, operational discipline, and strategic healthcare experience that will be invaluable as we grow our commercial operations and prepare for additional commercial opportunities for our SCD therapy," stated Eric Schlorff, CE

    11/17/25 8:43:00 AM ET
    $ICU
    Medical/Dental Instruments
    Health Care

    Leap Therapeutics Rebrands as Cypherpunk; Expands Leadership Team to Drive New Zcash Treasury Strategy

    Khing Oei appointed Chairman of the Board; Will McEvoy appointed Chief Investment Officer and Member of the Board; Cypherpunk Technologies Inc. announces acquisition of 203,775.27 ZEC. CAMBRIDGE, Mass., Nov. 12, 2025 /PRNewswire/ -- Leap Therapeutics, Inc. (NASDAQ:LPTX) today announced it will change its name to Cypherpunk Technologies Inc., and unveiled a digital asset treasury strategy to accumulate Zcash's native coin, ZEC. Cypherpunk has to date used $50 million of proceeds from the previously announced private placement to purchase 203,775.27 ZEC at an average purchase price of $245.37 per ZEC. In addition, the company also plans to change its ticker symbol to (NASDAQ:CYPH) as part of t

    11/12/25 7:00:00 AM ET
    $LPTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    ALX Oncology Appoints Board Member Barbara Klencke, M.D., as Interim Chief Medical Officer

    Dr. Barbara Klencke is an accomplished clinical leader with a distinguished track record in oncology drug development who currently serves on the Company's Board of Directors and will step down from the Board to join ALX as Interim Chief Medical Officer Alan Sandler, M.D. resigns as Chief Medical Officer and will return to his position serving on the Company's Board of Directors SOUTH SAN FRANCISCO, Calif., Sept. 12, 2025 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., ("ALX Oncology" or "the Company") (NASDAQ:ALXO), a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat cancer and extend patients' lives, today announced the appointment of Dr. Kl

    9/12/25 8:30:00 AM ET
    $ALXO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALXO
    $EHAB
    $FEMY
    $GRTS
    Financials

    Live finance-specific insights

    View All

    Enhabit Reports Fourth Quarter 2025 Financial Results

    Enhabit, Inc. (NYSE:EHAB), a leading home health and hospice care provider, today reported its results of operations for the fourth quarter ended Dec. 31, 2025. "Our fourth quarter 2025 results capped a pivotal year for Enhabit, delivering an emerging growth story with year over year increases in patient census, revenue and Adjusted EBITDA," said Barb Jacobsmeyer, CEO and president of Enhabit. "The consistent execution of our strategy throughout the year materially improved free cash flow, enabling us to further strengthen our balance sheet, positioning us well to accelerate growth and investment in 2026." QUARTERLY PERFORMANCE - CONSOLIDATED Net service revenue of $270.4 million

    3/4/26 4:10:00 PM ET
    $EHAB
    Medical/Nursing Services
    Health Care

    ALX Oncology Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

    - Clinical development for both the investigational CD47-inhibitor evorpacept and the novel EGFR-targeted antibody-drug conjugate ALX2004 remains on track following strong 2025 execution; company anticipates multiple meaningful data sets and milestones in the coming 12 to 18 months - - Evorpacept biomarker strategy validated by data from both the Phase 2 ASPEN-06 gastric cancer trial and the Phase 1b/2 breast cancer trial, independently suggesting CD47 overexpression is predictive of evorpacept activity and drives durable benefit in HER2-positive cancers - - Full biomarker analysis from Phase 1b/2 evorpacept-zanidatamab combination trial accepted for poster presentation at ESMO Breast Canc

    2/27/26 8:00:00 AM ET
    $ALXO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Enhabit to be Acquired by Kinderhook Industries

    Enhabit, Inc. Stockholders to Receive $13.80 per Share in Cash Enhabit, Inc. (NYSE:EHAB), a leading national home health and hospice provider, today announced it has entered into a definitive agreement to be acquired by Kinderhook Industries, LLC ("Kinderhook"), a middle market private equity firm, in an all-cash transaction for a total enterprise value of approximately $1.1 billion. Under the terms of the agreement, Enhabit stockholders will receive $13.80 per share in cash, which represents a premium of approximately 24.4% to the Company's closing stock price on February 20, 2026, the last full trading day prior to the announcement of the transaction, and a 33.8% premium to the Compan

    2/23/26 8:00:00 AM ET
    $EHAB
    Medical/Nursing Services
    Health Care

    $ALXO
    $EHAB
    $FEMY
    $GRTS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by MSP Recovery Inc.

    SC 13D/A - MSP Recovery, Inc. (0001802450) (Subject)

    12/17/24 4:05:04 PM ET
    $LIFW
    EDP Services
    Technology

    SEC Form SC 13G filed by Enhabit Inc.

    SC 13G - Enhabit, Inc. (0001803737) (Subject)

    11/14/24 9:12:39 PM ET
    $EHAB
    Medical/Nursing Services
    Health Care

    Amendment: SEC Form SC 13G/A filed by ALX Oncology Holdings Inc.

    SC 13G/A - ALX ONCOLOGY HOLDINGS INC (0001810182) (Subject)

    11/14/24 7:22:54 PM ET
    $ALXO
    Biotechnology: Pharmaceutical Preparations
    Health Care